Detection of PPROM With AmniSure PAMG-1 Rapid Immunoassay

NCT01637610 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 85

Last updated 2015-05-27

No results posted yet for this study

Summary

The investigators will test the hypothesis that in a preterm population with a gestational age of 16+0 and 36+6 weeks AmniSure PAMG-1 rapid immunoassay will be more accurate than conventional methods (speculum examination for combination of pooling, nitrazine and ferning) for the detection of Preterm Prelabour Rupture of Membranes (PROM).

Conditions

  • Preterm Premature Rupture of Fetal Membranes

Sponsors & Collaborators

  • University of Saskatchewan

    lead OTHER

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2013-08-31
Completion
2014-01-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01637610 on ClinicalTrials.gov